Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2021-12-22 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)
Regulatory Filings Classification · 100% confidence The document is a press release titled "EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for Acoustic Cluster Therapy (ACT®)". It discusses the allowance of a patent application in Europe, referencing previous grants in China and Japan, and highlights the company's Intellectual Property (IP) strategy. This type of announcement, concerning specific legal/IP developments (patent allowance), does not fit neatly into the primary financial reporting categories (10-K, IR, ER, MRQ). It is a specific corporate action announcement. Since there is no specific code for 'Patent Announcement', and it is a formal, non-routine corporate update, it best fits the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous regulatory or significant corporate news that isn't covered by other specific codes like M&A (TAR) or Capital Changes (CAP). Given the short length and announcement nature, RNS is the most appropriate classification.
2021-12-22 English
EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®
Capital/Financing Update Classification · 98% confidence The document is a press release dated December 21, 2021, announcing that EXACT Therapeutics AS was awarded a NOK 7.4 million research and innovation grant from the Norwegian Research Council (NRC). This announcement details funding for R&D activities related to their Acoustic Cluster Therapy (ACT®) platform, involving a partner (GE Healthcare). This type of announcement, concerning fundraising, grants, or financing activities, directly aligns with the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a Call Transcript (CT). Since it is a specific announcement about receiving funding/a grant, the most appropriate code is CAP (Capital/Financing Update). The document length is short (3499 chars), but it contains the full substance of the announcement, not just a notice that a report is attached, thus ruling out RPA/RNS based on the 'Menu vs Meal' rule.
2021-12-21 English
EXACT Therapeutics AS Awarded NOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®
Regulatory Filings Classification · 100% confidence The document is a short press release dated December 21, 2021, announcing that EXACT Therapeutics AS was awarded a NOK 7.4 million research and innovation grant from the Norwegian Research Council (NRC). This announcement details a specific event (grant award) related to R&D funding and partnership (with GE Healthcare). It is not a comprehensive annual report (10-K), an interim report (IR), a formal earnings release (ER), or a management discussion (MDA). Since it announces a specific, non-financial operational/funding event that doesn't fit the specific categories like DIRS, DIV, or CAP (which usually relates to equity/debt issuance), it falls best under the general 'Regulatory Filings' (RNS) category as a general corporate announcement, or potentially 'Capital/Financing Update' (CAP) due to the grant funding, but RNS is a safer general announcement category when the core topic is an award/partnership announcement rather than a direct capital raise or debt change. Given the options, RNS serves as the best fit for a general, non-standard regulatory announcement.
2021-12-21 English
Exact Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021
Report Publication Announcement Classification · 99% confidence The document is a short press release dated December 13, 2021, announcing that Exact Therapeutics AS will present a corporate overview at the DNB Nordic Healthcare Conference on December 16, 2021. It details the presenters, the time, and mentions that the presentation will be available online. Since this is an announcement about an upcoming presentation/event rather than the presentation material itself (AGM-R) or a formal financial report, and it is very short (2409 chars), it fits best as a general regulatory announcement or a notice regarding investor relations activities. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate event announcement that doesn't fit a more specific category like ER, IP, or AGM-R. It is not an Investor Presentation (IP) because it only announces the event, not providing the actual presentation content.
2021-12-13 English
Exact Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021
Regulatory Filings Classification · 100% confidence The document is a short announcement (2667 characters) stating that Exact Therapeutics AS will present a corporate overview at the DNB Nordic Healthcare Conference on a specific date. It details who will present and provides a link to where the presentation will be available. This structure—announcing participation in an external event where management will present company information—does not fit the definitions for a formal financial report (10-K, IR, ER) or a specific corporate action (DIV, CAP, SHA). It is an announcement about management presenting company information to investors, which is often categorized as an Investor Presentation (IP) or, given the context of an external conference presentation announcement, it can sometimes fall under Regulatory Filings (RNS) if it doesn't directly map to a specific investor relations document type. However, since the content is about management presenting an overview to investors/partners, it is most closely related to investor communication. Given the options, and that it is an announcement about a presentation, it is best classified as an Investor Presentation (IP) announcement, or if strictly following the 'announcement of report' rule, it might lean towards RNS/RPA. Since it is an announcement of a presentation (which is a form of investor material), IP is the most contextually relevant type, although RPA/RNS are also possibilities for short announcements. Given the content is about a corporate overview presentation, IP is the strongest fit for the *subject matter* being communicated, even if this specific document is the announcement of it. If we strictly follow the 'Menu vs Meal' rule, this is an announcement, not the presentation itself. Since there is no specific 'Presentation Announcement' code, and it's not a formal regulatory filing like 10-K, I will classify it as an Investor Presentation (IP) as the core subject matter is an investor presentation, or RNS as a general announcement. Given the nature of conference presentations, RNS (General Regulatory Filings) is a safe classification for announcements of participation in external investor events that aren't formal SEC filings or specific report releases.
2021-12-13 English
Exact Therapeutics AS to present at DNB Nordic Healthcare Conference on 16th December 2021
Report Publication Announcement Classification · 99% confidence The document is a short press release announcing that Exact Therapeutics AS will be presenting a corporate overview at the DNB Nordic Healthcare Conference on a specific date. It details who will present and provides contact information. Since the document is short (2413 characters) and its primary function is to announce participation in an event where a presentation will be given, it fits the description of an announcement regarding company activities or investor relations, but it is not a formal regulatory filing like a 10-K, an Earnings Release (ER), or a comprehensive Interim Report (IR). It is an announcement about an upcoming presentation, which is often categorized under general investor communications. Given the options, this type of announcement—a corporate update about an investor event—is best classified as a general Regulatory Filing (RNS) if a more specific category like 'Investor Presentation' (IP) is reserved for the actual presentation materials, or if it's a general corporate update. Since it's an announcement about an event where they will present, and not the presentation itself, RNS is the most appropriate fallback for a non-standard, non-mandatory disclosure, although it shares characteristics with investor relations updates. However, looking closely at the definitions, it is an announcement about corporate activity intended for investors. It is not a formal regulatory filing, nor is it a specific report. Given the context of investor communication, and lacking a specific 'Investor Event Announcement' code, RNS serves as the best general regulatory/corporate announcement category.
2021-12-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.